dividend stock

Home Depot's strong Q4 earnings mask concerning fundamentals, with same-store sales at 0.3% and 26x valuation warranting a HOLD rating despite long-term tailwinds.

Middlesex Water director purchased 2,000 shares for $109K, signaling confidence. Stock up 10% in 2026 post-rate approval, offering 2.73% dividend yield with 114-year payment history.

ADP stock down 35% from highs amid labor market concerns, but company maintains strong fundamentals, dividend growth, and trades below historical valuation multiples.

Realty Income doubles investment pace to $8B target for 2026, exceeding 2025's $6.3B deployment through acquisitions, partnerships, and European expansion.

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.

Enbridge authorizes CA$14B in 2025 capital projects with CA$39B backlog through 2033, supporting 5% annual earnings growth and consistent dividend increases.

Medtronic offers defensive stability through 48 years of dividend increases, essential medical devices, and consistent profitability across economic cycles.

Chevron offers a 3.9% dividend yield, more than triple the S&P 500 average, with 39 consecutive years of dividend increases supporting long-term income investors.

Coca-Cola extends dividend streak to 64 years with quarterly increase to $0.53/share, leveraging $11.4B free cash flow and 2.48% yield for steady investor income.

Coca-Cola appoints new CEO and Chief Digital Officer to drive modernization and growth, leveraging strong brand, diverse portfolio, and consistent dividend history.

Occidental Petroleum reports Q4 2025 earnings February 18 amid lower oil prices, though the company historically beats expectations. Geopolitical tensions could influence crude valuations.

Main Street Capital's conservative underwriting and diversified lower-middle-market strategy generated 17.2% annualized returns since 2008, doubling S&P 500 performance with a sustainable 6.09% dividend yield.

AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.